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Background: Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome is one of the most severe
forms of preeclampsia and aggravates both maternal and perinatal prognosis. The systematic review available in
Cochrane Library compared corticosteroid (dexamethasone, betamethasone, or prednisolone) given during
pregnancy, just after delivery or in the postnatal period, or both before and after birth, with placebo or no
treatment. Those receiving steroids showed significantly greater improvement in platelet counts which was greater
for those receiving dexamethasone than those receiving betamethasone. There was no clear evidence of any effect
of corticosteroids on substantive clinical outcomes. These benefits appear to be greater in Class I HELLP syndrome.
Objectives: To determine the effectiveness of dexamethasone for accelerating postpartum recovery in patients
with Class I HELLP syndrome in a multicenter randomized controlled trial.
Methods/Design: The study is a triple blind randomized controlled trial including women with class I HELLP
syndrome, and exclusion criteria were dexamethasone use in the last 15 days before diagnosis of HELLP syndrome;
chronic use of corticosteroids; chronic diseases that alter laboratory parameters of HELLP Syndrome, such as chronic
liver disease or purpura, patients unable to consent (coma or critical clinical condition) and without accompanying
persons that may consent to study participation.
Eligible patients will be invited to participate and those who agree will be included in the study and receive
placebo or dexamethasone according to a random list of numbers and subjects will receive the study medication
every 12 hours for two days.
During the study the women will be subject to strict control of blood pressure and urine output. Laboratory tests
will be performed at regular intervals during treatment and 24 hours and 48 hours after its suspension. If worsening
of clinical or laboratory variables is observed, a rescue scheme of dexamethasone will be administrated. This
proposal has already obtained approval of the local Institutional Review Board of the coordinating center (IMIP,
Recife, Brazil), all other participating centers and of the National Council for Ethics in Research (CONEP) of the
Brazilian Ministry of Health.
Trial Registration: Clinical Trials Register under the number NCT00711841.
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Hemolysis, elevated liver enzymes, and low platelets
(HELLP) syndrome is one of the most severe forms of
preeclampsia and aggravates both maternal and perinatal
prognosis [1]. HELLP syndrome can be diagnosed
during pregnancy or in the postpartum period and is
associated with increased maternal risks, including
liver hematoma, failure or rupture, pulmonary edema,
renal failure, hemorrhagic complications and death.
Perinatal prognosis is also poor due to preterm birth
and growth restriction [2-4].
As a variant of severe preeclampsia, the only definitive
treatment for HELLP syndrome is delivery of the baby
and removal of the chorionic villi [4]. No specific
treatment is available because the exact physiopathology
of the disease remains unknown [5-7]. For this reason,
treatment has historically been limited to controlling
blood pressure, prophylaxis against convulsions, and
termination of pregnancy [8].
Corticosteroids have been used for treating women
with HELLP syndrome both before and after delivery.
The suggested mechanism of action is a reduction in
platelet adhesion, reduction in spleen platelet removal, a
direct endothelial effect or rheological mechanism, and
finally an increase in platelet activation [2].
Initial observational studies demonstrated improvement
of maternal outcomes with administration of dexametha-
sone or betamethasone and small randomized clinical trials
found improvement in some laboratorial tests, especially
platelets count. The main outcomes, however, like death
and maternal morbidities (liver hematoma, pulmonary
edema, renal failure and abruptio placenta) were not
affected by corticosteroid therapy [9-13].
The largest double-blind, placebo-controlled clinical trial
carried out to date to evaluate this intervention was pub-
lished in 2005. There was no difference between the two
groups with respect to duration of hospitalization, recovery
time for laboratory or clinical parameters, complications, or
need for blood transfusion. These results remained
unchanged, even following analysis stratified according to
whether the patients were still pregnant or in the
postpartum [14]. Notwithstanding, a trend for better
maternal prognosis was found in most critically ill
patients, diagnosed with class I HELLP Syndrome
(platelets below 50.000/mm3). These patients had
faster recovery of platelets and shorter duration of
hospitalization.
A study carried out in a tertiary center in Brazil in
2008, failed to confirm any significant effect of the use
of dexamethasone on the clinical and laboratory parame-
ters of HELLP Syndrome in postpartum period. There
was no difference in the evolution of laboratory or clin-
ical parameters, frequency of maternal complications,
need for rescue scheme, or length of hospital stay amongpatients who received dexamethasone and those who
received placebo [15].
The systematic review available in the Cochrane Library
identified 11 randomized controlled trials involving 550
women that compared corticosteroid (dexamethasone,
betamethasone, or prednisolone) given during pregnancy,
just after delivery or in the postnatal period, or both before
and after birth, with placebo or no treatment. There was
no clear evidence of any effect of corticosteroids on sub-
stantive clinical outcomes. Those receiving steroids showed
significantly greater improvement in platelet counts which
was greater for those receiving dexamethasone than those
receiving betamethasone. The authors concluded that
evidences are insufficient to demonstrate substantive
improvement of clinical outcomes among women
receiving steroids for management of HELLP syndrome.
Notwithstanding, they suggest that the use of corticoste-
roids may be justified in clinical situations in which
increased rate of recovery in platelet count is considered
clinically worthwhile [16].
HELLP syndrome is a rare disease and its more severe
forms are even rarer. To evaluate only the most severely ill
patients, who are possibly those who would most benefit
from corticosteroid therapy as shown in the study carried
out by Fonseca et al. [14], various centers would have to be
involved to achieve an adequate sample size with sufficient
power to define infrequent outcomes such as death.
The overall objective of this study is to determine the
effectiveness of dexamethasone to accelerate the postpar-
tum recovery of patients with class I HELLP syndrome.
Objectives and hypothesis
The overall objective is to determine the effectiveness of
dexamethasone for accelerating postpartum recovery in
patients with Class I HELLP syndrome in a multicenter
randomized controlled trial.
Specific objectives
Analyzing patients with class I HELLP Syndrome
randomized to receive dexamethasone or placebo, the
specific objectives are to compare:
Primary outcome
 Frequency of composite maternal morbidity
(acute pulmonary edema, eclampsia, bleeding
manifestations, shock, coma, renal failure, liver
failure, DIC, blood transfusion or death).
Secondary outcomes
 Laboratory parameters during and after treatment
(hemoglobin, platelets, LDH, transaminases and
bilirubin).
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 Frequency of maternal complications: acute
pulmonary edema, bleeding, acute renal failure
and death.
 Need for rescue therapy regimen during the
observation period.
 Time elapsed between the first dose of medication
(dexamethasone or placebo) and egress (discharge
or death).
Main hypothesis
In patients with class I HELLP Syndrome receiving
dexamethasone, in comparison with placebo:
 The frequency of composite maternal morbidity
is lower.
 Hemoglobin and platelets levels are greater while
LDH, transaminases and bilirubin levels are lower.
 Better diuresis is achieved.
 Maternal complications are less frequent.
 There is less need for rescue therapy regimen during
the observation period.
 Time elapsed between the first dose of medication
and hospital discharge is lower.
Methods/Design
Study design
The present study is a triple blind randomized controlled
trial.
Study population and location
The study population will include all eligible women
with Class I HELLP Syndrome hospitalized in the
participating centers during the data collection period.
Eligibility criteria
The inclusion criterion is the presence of Class I HELLP
syndrome, both in antepartum or postpartum period.
Exclusion criteria are: dexamethasone use in the last 15
days before diagnosis of HELLP syndrome; chronic use
of corticosteroids; chronic diseases that alter laboratory
parameters of HELLP Syndrome, such as chronic liver
disease or purpura; patients unable to consent (coma or
critical clinical condition) and without accompanying
persons that may consent to study participation.
Procedures for selecting participants and randomization
Eligible patients will be invited to participate and those
who agree will be included in the study and receive
placebo or dexamethasone according to a random list
of numbers generated by the Random Allocation Software
Ispharan Iran, version 1.0. This list of randomization will
be provided by the statistician to the pharmacist who will
be responsible for preparing the packages containingeither the dexamethasone or placebo, both in an identical
presentation, with the identification number of list labeled.
This procedure will be followed in order to guarantee the
concealment of allocation of patients in both arms.
Considering dexamethasone has no important immediate
identifiable effects, either patients and medical staff
should be blind of the intervention condition in each
case. Study medication and placebo, after delivered by
the pharmaceutical industry to the pharmacy of the
coordinating center, will be packed as previously described
and according the random list. The pharmacy will be
responsible for sending sets of 5 or 10 packages to
each center depending on their performance on patients’
enrollment. The subjects will receive the study medication
every 12 hours for two days.
During the observation period the women will be subject
to strict control of blood pressure and urine output
(diuresis evaluated spontaneous or urinary catheter).
Laboratory tests will be performed at regular intervals
of 24 hours (blood count, coagulation, renal and hepatic
function) during treatment and 24 hours and 48 hours
after its suspension. If investigators observe worsening of
clinical or laboratory variables the study protocol will be
interrupted and dexamethasone will be administrated.
The same will be done if after the end of the two days the
clinical situation deteriorates or does not improve. The
patient will be considered as belonging to the group that
she was originally randomized to, independent of later use
of dexamethasone (type analysis intention to treat),
recording such cases the need for "rescue therapy".
Sample size calculation
The sample size for the trial was calculated using public
domain software Openepi version 2.3.1. We assumed a
rate of severe maternal morbidity condition of 50%
among patients with syndrome HELLP in placebo group
and 35% in patients treated with dexamethasone. With a
power of 80% and an alpha error of 5%, 364 patients
would be needed to demonstrate this difference. This
number was increased to 400 patients for allowing for
eventual losses and exclusions after randomization.
Variables
Independent variable
use of corticosteroid (dexamethasone) or placebo.
Dependent variables
composite maternal morbidity, laboratory parameters
during and after treatment (hemoglobin, platelet count,
LDH, transaminases and bilirubin), diuresis during and
after treatment, maternal complications, need for rescue
therapy regimen, time elapsed between the first dose of
medication (dexamethasone or placebo) and egress (dis-
charge or death).
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 Hypertensive disorders of pregnancy: defined
according to the National High Blood Pressure
Education Program Working Group on High Blood
Pressure in Pregnancy [17].
 Maternal complications: any of these conditions:
acute pulmonary edema, eclampsia, bleeding
manifestations, shock, renal failure, coma, liver
failure and blood transfusion.
 Composite maternal morbidity: presence of one or
more of the following findings: acute pulmonary
edema, eclampsia, bleeding manifestations, shock,
coma, renal failure, liver failure, DIC, blood
transfusion and death.
 HELLP syndrome: defined according to the criteria
defined by Sibai [1]: 1. Hemolysis: characterized as
the presence of abnormal peripheral blood smear
(schystocytosis, anisocytosis, echinocytosis,
poikilocytosis) associated with increased serum total
bilirubin (> 1.2 mg%) or LDH increased (> 600 U/l);
2. Increased liver enzymes: when the serum AST is
greater than 70 U/l or serum lactate dehydrogenase
was higher than 600 U/l; 3. Thrombocytopenia:
considered when the platelet count is less than
100.000/mm3.
 Rescue corticosteroid scheme: use of ampoules of
intravenous dexamethasone in patients who had no
improvement in laboratory tests or worsened in the
course of the drug and therefore had the outline of
the study (dexamethasone or placebo) suspended.
Will also be adopted in patients who, after two days
persisted with very altered laboratory tests.Data collection procedures
Data collection
Data will be inserted in an electronic clinical research
form (CRF) especially developed for this study in an
electronic platform (OpenClinica®) [18], which will be
provided to the participating centers by the coordinating
center. It was created by collaborators in CEMICAMP
(Center for Studies in Reproductive Health of Campinas).
After manual data collection in the questionnaire, it will
be inserted in the electronic CRF in the project website
and sent to the central database for storage. This was built
in an exclusive computer, plus an external drive for
backup, in an informatics unit with emergency power
supply and automatic saving. Data missing in medical
charts should be collected from other sources, such as
hospital's database, prenatal cards, transference documents,
etc. There will be a periodic communication between the
coordinating center and the participating centers during
the data collection period.Every center will have a restricted area in the site,
where they will have access only to their own cases
through a password, with different levels of access
depending on the hierarchical structure of the study in
that site and the role played by personnel involved in the
study. The principal investigators at the coordinating
center and the administrator of the network will have
global access to all cases. Summary information will be
available in the form of monthly graphs and tables
containing the number of cases included by each center
and the distribution of referred diagnoses, provided by the
coordinating center in the website's homepage.
In a monthly basis, the participating institutions will
inform through the website the overall number of
deliveries, live births and patients with HELLP syndrome
(complete and partial) that occurred in the previous
month and the total number of patients included. This
data will be checked by the main local researcher at the
end of each month. In order to minimize doubts from
researcher assistants during data collection, a Manual of
Operation will be developed with all information
necessary to complete questionnaires and electronic
CRF, use the internet, access to each center's database,
standardized diagnostic definitions, among others.
A meeting will be held with all participating centers
before the beginning of data collection, in order to
standardize concepts and the data collection process
with the completion of questionnaires. Training regarding
the use of the electronic form will be performed by all
centers, coordinated by the principal investigators, just
before data collection is initiated, in order to standardize
data collection. A final meeting will be held with the local
principal investigators at the end of data collection process
to discuss results, schedule final analyses, organize articles
to be submitted for publication and define the responsibility
and role of each person involved in this process.
Data analysis plan
The data analysis will be performed using the public
domain software Epi Info version 7 (Centers for Disease
Control and Prevention, Atlanta, GA), or the newest
available version under the intention to treat principle. The
statistician and the investigators will remain blind to the
treatment groups until the tables will be prepared and the
analysis concluded. The approach for analysis will be that
showed in Figure 1 using an intention-to-treat strategy and
following the correspondent recommendations from the
CONSORT statement [19]. The characteristics of the
participants in each group will be compared with Student’s
t test for continuous variables with normal distribution and
Mann–Whitney U test for discrete and ordinal variables or
those with non-normal distribution. Categorical variables
will be compared with Pearson’s χ2 test or Fisher’s exact
test, as appropriate. P values for all tests will be two tailed
Figure 1 Study design and population (CONSORT, 2010) [19].
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95% confidence intervals will be calculated as a measure
of relative risk. The number needed to treat (NNT) and
its 95% confidence interval will be calculated for the
outcomes in which a beneficial effect of dexamethasone
treatment is achieved, using the EBM calculator
[http://moosenose.com/EBCalculator.htm]; in case of
adverse effects the number needed to harm (NNH)
and its 95% confidence will also be calculated.
Quality control
The local researchers will maintain a record of problems
occurred during the study and any doubt should be
solved with the project's national coordinators and the
Steering Committee.
Study planning
In August of 2010, a meeting was held with the participat-
ing institutions in Recife, Pernambuco (northeast of Brazil)
when representatives from 21 Brazilian health institutions
were present. All these centers participated in the Brazilian
Network for Studies on Reproductive and Perinatal Health
[20] created in Campinas, Brazil, in 2008.
At this meeting, we presented the main points of the
initial version of the proposal and all centers wereinvited to participate by filling out a form with the main
characteristics of their institutions. Those centers that
have met all requirements (at least 15 cases of HELLP
syndrome treated per year with a minimum of five
severe cases) were officially invited to participate and
received a copy of the final draft, which was improved
with substantial contributions from representatives of
the participating centers.
Ethical issues
The original protocol of this research proposal has already
obtained approval of the local Institutional Review Board
from the coordinating center (IMIP, Recife, Brazil), from all
other participating centers and of the National Committee
for Ethics in Research (CONEP) of the Brazilian Ministry of
Health, under the number 1255. The collaborating centers
were only definitely incorporated in the study after
the proposal has been approved by their respective
Institutional Review Boards (IRB). The protocol also
was published in the Clinical Trials Register under
the number NCT00711841 (http://clinicaltrials.gov/
ct2/show/NCT00711841). Patients with Class I HELLP
syndrome will only be included if they agree to participate
and sign the informed consent. In case of patients unable to
consent (coma or critical clinical condition) the consent to
participate will be given by the accompanying person. All
principles related to research in human beings established
by the Brazilian National Health Council according to the
Declaration of Helsinki will be followed. The confidentiality
on women's data and medical care will be ensured
regardless of whether they participate in the study or not.
Discussion
Technical and scientific contributions of the study
Hypertension is the first cause of maternal death in Brazil
and the third in the world. HELLP syndrome is one of the
most severe forms of the disease and it is associated with
several complications that include: hemorrhage, DIC, renal
failure, liver failure and maternal death. These complica-
tions are strongly associated with Class I HELLP Syndrome
and the possibility of accelerating recovery in these patients
is very attractive with potential maternal benefits and
substantial reduction in costs for health services. Although
Class I HELLP Syndrome is relatively rare, we have a great
number of patients with severe preeclampsia in the partici-
pant centers and a higher proportion of complicated cases
because prenatal care is still inadequate and a lot of preg-
nant women are admitted with deteriorated clinical condi-
tion. As for instance, in the coordinating center, IMIP, the
rate of HELLP Syndrome among patients with preeclamp-
sia is so high as 16,2%. Furthermore, to determine if corti-
costeroids are indicated in this scenario will be relevant not
only to Brazil but also to other countries with elevated
frequency of hypertensive syndromes in pregnancy.
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